Human-Induced Pluripotent Stem Cells Manufactured Using a Current Good Manufacturing Practice-Compliant Process Differentiate Into Clinically Relevant Cells From Three Germ Layers
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
The discovery of reprogramming and generation of human-induced pluripotent stem cells (iPSCs) has revolutionized the field of regenerative medicine and opened new opportunities in cell replacement therapies. While generation of iPSCs represents a significant breakthrough, the clinical relevance of iPSCs for cell-based therapies requires generation of high-quality specialized cells through robust and reproducible directed differentiation protocols. We have recently reported manufacturing of human iPSC master cell banks (MCB) under current good manufacturing practices (cGMPs). Here, we describe the clinical potential of human iPSCs generated using this cGMP-compliant process by differentiating them into the cells from all three embryonic germ layers including ectoderm, endoderm, and mesoderm. Most importantly, we have shown that our iPSC manufacturing process and cell culture system is not biased toward a specific lineage. Following controlled induction into a specific differentiation lineage, specialized cells with morphological and cellular characteristics of neural stem cells, definitive endoderm, and cardiomyocytes were developed. We believe that these cGMP-compliant iPSCs have the potential to make various clinically relevant products suitable for cell therapy applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Disease-Specific Induced Pluripotent Stem Cells.
Park, I.-H., Arora, N., Huo, H., Maherali, N., Ahfeldt, T., Shimamura, A., Lensch, M. W., Cowan, C., Hochedlinger, K., & Daley, G. Q. (2008) · Cell · doi:10.1016/j.cell.2008.07.041 · Cited by 2,196 · cited 1×
“J Am Coll Cardiol (2014) 64(5):436–48.”
Efficient differentiation of human embryonic stem cells to definitive endoderm
D'Amour, K. A., Agulnick, A. D., Eliazer, S., Kelly, O. G., Kroon, E., & Baetge, E. E. (2005) · Nature Biotechnology · doi:10.1038/nbt1163 · Cited by 1,730
Chemically defined generation of human cardiomyocytes
Burridge, P. W., Matsa, E., Shukla, P., Lin, Z. C., Churko, J. M., Ebert, A. D., Lan, F., Diecke, S., Huber, B., Mordwinkin, N. M., et al. (2014) · Nature Methods · doi:10.1038/nmeth.2999 · Cited by 1,606
Induced pluripotent stem cell technology: a decade of progress.
Shi, Y., Inoue, H., Wu, J. C., & Yamanaka, S. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.245 · Cited by 1,525
Induced pluripotent stem cells from a spinal muscular atrophy patient
Ebert, A. D., Yu, J., Rose, F. F., Mattis, V. B., Lorson, C. L., Thomson, J. A., & Svendsen, C. N. (2009) · Nature · doi:10.1038/nature07677 · Cited by 1,441
Kirkeby, A., Grealish, S., Wolf, D. A., Nelander, J., Wood, J., Lundblad, M., Lindvall, O., & Parmar, M. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.04.009 · Cited by 662 · cited 1×
“Differentiation of PSCs into NSCs and functional neurons has been reported by several groups using different cytokines and small molecules (16, 34, 35).”
BackgroundRing, D. B., Johnson, K. W., Henriksen, E. J., Nuss, J. M., Goff, D., Kinnick, T. R., Ma, S. T., Reeder, J. W., Samuels, I., Slabiak, T., et al. (2003) · Diabetes · doi:10.2337/diabetes.52.3.588 · Cited by 532 · cited 1×
“Treatment of LiPSCs with hLIF and 2 small molecules (CHIR99021 and SB431542) induced the cells into a primitive NSCs by modulation of canonical Wnt signaling (GSK3 inhibition) (17) and TGF-beta/Activin receptors (18).”
BackgroundModeling ALS with motor neurons derived from human induced pluripotent stem cells
Sances, S., Bruijn, L. I., Chandran, S., Eggan, K., Ho, R., Klim, J. R., Livesey, M. R., Lowry, E., Macklis, J. D., Rushton, D., et al. (2016) · Nature Neuroscience · doi:10.1038/nn.4273 · Cited by 289
HLA engineering of human pluripotent stem cells
Riolobos, L., Hirata, R. K., Turtle, C. J., Wang, P.-R., Gornalusse, G. G., Zavajlevski, M., Riddell, S. R., & Russell, D. W. (2013) · Molecular Therapy · doi:10.1038/mt.2013.59 · Cited by 253 · cited 1×
“There are still major obstacles toward clinical application of human iPSC: high cost of production and post-transplantation immunological reaction, which highlights the need for generation of large HLA-matched MCBs from donors with selected haplotypes (28, 29) or by genetic manipulation of human iPSC prior to differen…”
BackgroundToward the development of a global induced pluripotent stem cell library
Turner, M., Leslie, S., Martin, N. G., Peschanski, M., Rao, M., Taylor, C. J., Trounson, A., Turner, D., Yamanaka, S., & Wilmut, I. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.08.003 · Cited by 245 · cited 1×
“There are still major obstacles toward clinical application of human iPSC: high cost of production and post-transplantation immunological reaction, which highlights the need for generation of large HLA-matched MCBs from donors with selected haplotypes (28, 29) or by genetic manipulation of human iPSC prior to differen…”
BackgroundSelf-citation
Cited by
End-to-End Platform for Human Pluripotent Stem Cell Manufacturing
Pandey, P. R., Tomney, A., Woon, M. T., Uth, N., Shafighi, F., Ngabo, I., Vallabhaneni, H., Levinson, Y., Abraham, E., & Friedrich Ben-Nun, I. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010089 · Cited by 42
Suresh Babu, S., Duvvuru, H., Baker, J., Switalski, S., Shafa, M., Panchalingam, K. M., Dadgar, S., Beller, J., & Ahmadian Baghbaderani, B. (2023) · Biotechnology Reports · doi:10.1016/j.btre.2023.e00784 · Cited by 22
“To properly address the manufacturing challenges for commercialization of iPSC-based therapies, we propose a few initiatives including focusing on detailed iPSC characterization [4], long-term stability of cGMP compliant iPSC [6], use of computer-controlled 3D bioreactor-based manufacturing process to reduce the labor…”
BackgroundMethodSelf-citation
Metadata
- Authors
- Shafa, M., Yang, F., Fellner, T., Rao, M. S., & Baghbaderani, B. A.
- Venue
- Frontiers in Medicine
- Publisher
- Frontiers Media SA
- Published
- 2018-03-15
- Volume
- 5
- Pages
- 69-69
- ISSN
- 2296-858X (ISSN-L)
- OpenAlex
- W2791231975
- Cited by
- 36
- References
- 15
- FWCI
- 1.57
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Human-Induced Pluripotent Stem Cells Manufactured Using a Current Good Manufacturing Practice-Compliant Process Differentiate Into Clinically Relevant Cells From Three Germ Layers. https://app.cochat.ai/papers/10.3389/fmed.2018.00069
- The paper
- Shafa, M., Yang, F., Fellner, T., Rao, M. S., & Baghbaderani, B. A. (2018). Human-Induced Pluripotent Stem Cells Manufactured Using a Current Good Manufacturing Practice-Compliant Process Differentiate Into Clinically Relevant Cells From Three Germ Layers. Frontiers in Medicine. https://doi.org/10.3389/fmed.2018.00069
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.